Feedback from Cloud or HCP to Payer or Patient via Meter or Cell Phone

Abstract

Presented herein are one or more software applications to help a user manager their diabetes. Embodiments and descriptions of the various applications are provided below in conjunction with an analyte measurement device.

1 - 19 . (canceled) 
     
     
         20 . A method, comprising:
 displaying a chart having median glucose as a first axis and glucose variability as a second axis; and   displaying an identifier on the chart corresponding to a median glucose value and a glucose variability value for sample data from a first patient, wherein the identifier represents a state of glucose control for the first patient.   
     
     
         21 . The method of  claim 20 , wherein glucose variability is defined by the difference between the median glucose value and a predetermined percentile value of glucose. 
     
     
         22 . The method of  claim 21 , wherein the predetermined percentage value is 10 percent. 
     
     
         23 . The method of  claim 20 , comprising:
 displaying a graphical overlay representing a chronic clinical risk on the chart, wherein the graphical overlay derived representing retinopathy risk is based on eAG and median glucose values for a population of patients.   
     
     
         24 . The method of  claim 23 , wherein the chronic clinical risk is retinopathy risk. 
     
     
         25 . The method of  claim 24 , comprising:
 displaying a graphical overlay representing an acute risk on the chart, wherein the graphical overlay representing acute risk of hypoglycemia comprises one or more lines of hypoglycemia occurrences per a given time period.   
     
     
         26 . The method of  claim 25 , wherein the acute risk is a risk of hypoglycemia. 
     
     
         27 . The method of  claim 26 , comprising:
 directing patient treatment based on the position of the identifier representing the state of glucose control for the first patient with respect to the graphical overlays for retinopathy risk and/or acute risk of hypoglycemia.   
     
     
         28 . The method of  claim 20 , comprising:
 displaying a graphical overlay for one or more clinical risks on the chart, wherein the graphical overly of the one or more clinical risks is associated with one or more axis of the chart.   
     
     
         29 . The method of  claim 20 , comprising:
 determining lines of constant hypoglycemia rates, wherein the lines of constant hypoglycemia rates are based on a number of occurrences of hypoglycemia per a given time period.   
     
     
         30 . The method of  claim 29 , wherein the lines of constant hypoglycemia rates are determined from a number of occurrences of hypoglycemia per a given time period for a sample population of patients. 
     
     
         31 . The method of  claim 29 , wherein the lines of constant hypoglycemia rates are parallel approximations. 
     
     
         32 . The method of  claim 29 , comprising:
 determining a threshold line of constant hypoglycemia rate; and   displaying a hypoglycemia risk zone having a border line on the threshold line of constant hypoglycemia rate.   
     
     
         33 . The method of  claim 32 , comprising:
 determining a target A1c level corresponding to a median glucose value; and   displaying a target zone defined by the target A1c level and the border line of the hypoglycemia risk zone.   
     
     
         34 . The method of  claim 33 , comprising:
 displaying a buffer zone along the border line and adjacent the target zone; and   defining the remaining area of the chart as a fourth zone.   
     
     
         35 . The method of  claim 34 , comprising:
 directing treatment of the first patient based on the position of the identifier representing the state of glucose control for the first patient with respect to the hypoglycemia risk zone, target zone, buffer zone, and/or fourth zone.   
     
     
         36 . The method of  claim 33 , comprising:
 directing treatment of the first patient based on the position of the identifier representing the state of glucose control for the first patient with respect to the hypoglycemia risk zone and/or the target zone.   
     
     
         37 . The method of  claim 20 , wherein the identifier representing the state of glucose control for the first patient is calculated from the sample data. 
     
     
         38 . The method of  claim 20 , wherein the identifier representing the state of glucose control for the first patient is calculated from fitting the sample data to a probability distribution. 
     
     
         39 . The method of  claim 38 , wherein the probability distribution is a gamma probability distribution. 
     
     
         40 . The method of  claim 20 , wherein the identifier comprises a bootstrap point cloud. 
     
     
         41 . The method of  claim 40 , comprising:
 defining a treatment recommendation point based on a predetermined threshold percentage value, wherein the predetermined threshold percentage value correlates to an acceptable probability threshold of being in a hypoglycemia risk zone on the chart.   
     
     
         42 . The method of  claim 20 , wherein the identifier comprises a boundary line of a bootstrap point cloud. 
     
     
         43 . The method of  claim 20 , wherein the identifier comprises contour plots of a probability distribution function for the state of glucose control for the first patient, wherein the contour plots represent uncertainty levels for the estimate. 
     
     
         44 . The method of  claim 43 , wherein the probability distribution function is based on a first testing schedule over a first time period. 
     
     
         45 . The method of  claim 44 , comprising:
 displaying a graphical overlay representing retinopathy risk on the chart, wherein the graphical overlay derived representing retinopathy risk is based on eAG and median glucose values for a population of patients; and   displaying a graphical overlay representing acute risk of hypoglycemia on the chart, wherein the graphical overlay representing acute risk of hypoglycemia comprises one or more lines of hypoglycemia occurrences per a given time period.   
     
     
         46 . The method of  claim 45 , comprising:
 directing patient treatment based on a comparison of the contour lines with respect to the graphical overlays for retinopathy risk and/or acute risk of hypoglycemia.   
     
     
         47 . The method of  claim 45 , comprising:
 directing patient treatment to a second testing schedule based on a comparison of the contour lines with respect to the graphical overlays for retinopathy risk and/or acute risk of hypoglycemia.   
     
     
         48 . The method of  claim 44 , wherein the first testing schedule is a self-monitored blood glucose (SMBG) testing schedule. 
     
     
         49 . The method of  claim 43 , wherein contour plots are associated with one or more clinical risks. 
     
     
         50 . The method of  claim 49 , wherein the one or more clinical risks comprises retinopathy risk and/or acute risk of hypoglycemia. 
     
     
         51 . The method of  claim 49 , wherein different SMBG testing schedules are collected, and wherein for each schedule, the contour plots are computed a priori from population data. 
     
     
         52 . The method of  claim 51 , wherein the population data is comprised of CGM values or SMBG data taken every 15 minutes or faster. 
     
     
         53 . The method of  claim 51 , wherein the population data is obtained from human studies wearing CGM systems. 
     
     
         54 . The method of  claim 51 , wherein the population data is obtained from in-silico human models representing a wide range of demographics and/or state of diabetes. 
     
     
         55 . The method of  claim 51 , wherein the contour plots from the population data is projected along the gradient of a particular clinical risk. 
     
     
         56 . The method of  claim 51 , wherein adequate and inadequate areas in the glucose control chart are identified for each combination of SMBG testing schedule and clinical risk. 
     
     
         57 . The method of  claim 56 , comprising:
 identifying the areas of inadequacy on the chart.   
     
     
         58 . The method of  claim 49 , comprising:
 recommending a SMBG testing schedule specific to a latest state of glucose control for the first patient.   
     
     
         59 . The method of  claim 58 , comprising:
 identifying adequate and inadequate areas in the chart; and   determining whether initial data under the recommended SMBG testing schedule falls within the adequate or the inadequate area.   
     
     
         60 . The method of  claim 49 , comprising:
 identifying adequate and inadequate areas in the chart; and   recommending a SMBG testing schedule to position a next predicted state of glucose control in the adequate area.   
     
     
         61 - 116 . (canceled)